XNAS · Healthcare · Biotechnology
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.20 | -0.23 | -15.00% | $0 | ❌ Miss | +0.53% | -17.35% | — |
| 2026-03-12 | Q4 2025 | -0.16 | -0.37 | -131.25% | $0 | ❌ Miss | +0.27% | +1.33% | -8.53% |
| 2025-11-04 |
| Q3 2025 |
| -0.21 |
| -0.19 |
| +9.52% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.19 | -0.26 | -36.84% | $0 | ❌ Miss | +12.78% | +0.31% | +1.80% |
| 2025-03-20 | Q4 2024 | — | -0.22 | — | $0 | — | -2.24% | -13.53% | -11.00% |
| 2024-11-07 | Q3 2024 | — | -0.17 | — | $0 | — | +1.63% | -8.32% | +4.96% |
Showing last 6 quarters.